Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) Presenting at the 62nd Annual ASH Meeting

Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) Presenting at the 62nd Annual ASH Meeting

Actinium Pharmaceuticals (NYSE: ATNM) Trending Biopharma Stock

Biotech a 2021 Market Driver

Current price $10.84 per share (Friday’s close)
Outstanding shares (est.) 13.59 million
Float (est.) 12.78 million shares

Why we like ATNM shares at their current price:

Tiny float
Proprietary, patented technology
Late-stage clinical trial
High institutional ownership
Long term cash runway
Chart setup indicates potential breakout

As you are reading this, ATNM is at the 62nd American Society of Hematology (ASH) Annual Meeting, which is being held virtually December 5-8, 2020. During the meeting, the company will present four abstracts detailing the Company’s clinical trial data for Iomab-B and Actimab-A. 

ATNM is a company on the forefront of new medical treatments. The company aims to combine the targeting ability of antibodies with the cell killing ability of radiation and it’s the cell killing with radiation we want to discuss today.

Actinium’s Antibody Warhead Enabling (AWE) platform delivers a potent tumor-destroying dose of the radiation from the actinium warhead. The AWE technology, delivering cancer killing therapy and an electrical charge is proprietary to ATNM.

The AWE technology is proprietary to ATNM, no one else has anything like it.

The AWE technology can and is being used/tested by other pharma companies in conjunction with their own cancer therapies. Actinium has over 100 patents on its AWE technology.

The power of this technology lies in its alpha emitting payload actinium-225. It emits a powerful dose of high energy but only over a very short distance – about the distance of a few cells or less than the thickness of a piece of paper.

This focuses the radiation on the cancer cells and limits exposure to normal tissues. The energy delivered is so strong that one or two targeted actinium warheads may be sufficient to kill a tumor cell.

The AWE conjugate is made up of three main component parts, (1) the targeting vehicle, which may be a monoclonal antibody, an antibody fragment, or a small molecule like a peptide; (2) the potent actinium-225 radioactive warhead; and (3) a linker-chelator that connects the targeting vehicle to the actinium warhead.

AWE technology has been evaluated in multiple preclinical models of both blood cancers, such as acute myeloid leukemia, and solid tumors like breast cancer, prostate cancer and colon cancer demonstrating broad potency across several different tumor types.

These preclinical models showing that AWE may be effective against solid cancer tumors speaks to the importance of the technology and the potential it may create for ATNM. The AWE conjugates are administered through an IV, not complicated, and this delivery system can potentially send any company’s tumor targeting vehicle to its destination.

In 2018, Actinium announced a collaborative research partnership with Astellas Pharma, Inc. that leverages Actinium’s AWE Technology Platform.

ATNM has developed a technology that could take it beyond the borders of its own research. The company has developed this potential vertical that is barely being utilized beyond the scope of its own research. We believe AWE could be the crown jewel in the Actinium value analysis.

The company had a cash position of $48 million at the end of the third quarter that should allow them to meet their development objectives well into 2022.

The low public float of 12.7M shares means ATNM shares can move quickly.

In Actinium’s current chart, we note the RSI (14) at 48.63 and a setup that shows a potential near term breakout.

Now that you see why we like the setup here. Our full report will be out soon.

Stay tuned and stay informed,

The Traders News Group



Privacy Policy and Disclaimer
Your Consent
By using our site, you consent to our online privacy policy and disclaimer.
Do we disclose any information to outside parties?
We do not sell, trade, or otherwise transfer to outside parties your personally identifiable information.
What information do we collect?
We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.
When registering on our site, as appropriate, you may be asked to enter your: e-mail address and or mobile number.
What do we use your information for?
When we collect your email or mobile number it is used for one purpose to send you the information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.
Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.
We send periodic emails
The email address you provide may be used to send you information, respond to inquiries, and/or other requests or questions.
How do we protect your information?
We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and sms messages to you.
Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act. We therefore will not distribute your personal information to outside parties without your consent.
Online Privacy Policy Only
This online privacy policy applies to information collected through our website and social media platforms.
Contacting Us
If there are any questions regarding this privacy policy or disclaimer you may contact us using the information below.
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. TNS LLC’s parent company has been compensated sixteen thousand five hundred dollars cash via bank wire by legends media llc for this weeks coverage of atnm. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.
TNS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. TNS LLC is not a Broker/Dealer and does not engage in high frequency trading.